Skip to main content

Cozadd Bruce C's Form 4 filing

Jazz Pharmaceuticals plc (JAZZ) · filed Jan 5, 2022

Accession no.
0001765581-22-000002
Filed
Jan 5, 2022
Trade date
Jan 3, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $740.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cozadd Bruce CCIK 0001193210Director, Officer (Chairman & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2022Ordinary SharesMOption exerciseAcquired+9,700$46.83+$454,251328,251Direct
Jan 3, 2022Ordinary SharesSSaleDisposed−1,819$126.72F2−$230,503.68326,432Direct
Jan 3, 2022Ordinary SharesSSaleDisposed−1,181$127.58F3−$150,671.98325,251Direct
Jan 3, 2022Ordinary SharesSSaleDisposed−2,651$128.67F4−$341,104.17322,600Direct
Jan 3, 2022Ordinary SharesSSaleDisposed−140$129.34F5−$18,107.6322,460Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2022Ordinary SharesMOption exerciseDisposed−9,700$0.00$067,832Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $126.14 to $127.12. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

F3

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $127.15 to $127.945. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

F4

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $128.23 to $129.09. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

F5

Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $129.285 to $129.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)